I Ttp

Pr Newswire - Dec 19th, 2024

Score 7.2

TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke (AIS) and TTP

TGD001 is being developed to offer patients with clotting disorders a faster, safer and more effective treatment than today's standard of care – saving lives and reducing disability Following the Phase 1 safety study, TargED intends to further develop TGD001 in patients with AIS and iTTP...